The IP & Science business of Thomson Reuters has announced a preview of its latest intelligence solution, Thomson Reuters Cortellis for Clinical Trials Intelligence.
Scheduled for release in early 2013, this capability will provide drug development and clinical professionals with the critical information necessary to evaluate market opportunities, identify potential barriers, and establish informed decisions about clinical trial design and operations.
Cortellis for Clinical Trials Intelligence is the latest information solution offered through Thomson Reuters Cortellis, the industry's premier Life Sciences information delivery platform. It claims to have the broadest remit of any clinical trials database including a 45-year history of clinical outcomes, as well as the latest market competitive activity from established and emerging markets such as China, India and Brazil. This solution enables a customer to integrate their proprietary research data with comprehensive clinical trials protocols and outcomes, drug pipeline, biomarker, regulatory, financial and patent information from Thomson Reuters. With its integrated analytics tools and visualisations, users will have greater opportunities to maximise the value of clinical trial content to inform internal strategy and decision-making.
Cortellis for Clinical Trials Intelligence optimises critical clinical trial functions by equipping R&D strategists with knowledge that helps them discover market opportunities and potential barriers. This solution enables efficient searching for competing trials as well as identifying countries rich in target populations. By empowering clinical development teams to better understand trial design trends, Cortellis for Clinical Trials Intelligence allows them to design better and faster trials, while enabling marketing teams to pinpoint likely competitors.
The experts of Thomson Reuters' professional services also utilize Cortellis for Clinical Trial Intelligence and the company's other intelligence solutions - including translational medicine offerings and clinical development and portfolio strategy benchmarking - to support specific customer projects.
